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ABSTRACT
Objective: Iron isomaltoside (MonoferVR ) is a high-dose intravenous iron preparation with good
tolerability and efficacy in inflammatory bowel disease (IBD) patients with iron deficiency anaemia
(IDA). This trial evaluates the safety and efficacy, including effect on intact fibroblast growth factor
23 (iFGF23) of a high single dose and cumulative doses of iron isomaltoside in IBD patients with
IDA.
Materials and methods: The trial was a prospective, open-label, multi-centre trial conducted in IBD
patients with IDA. Based upon haemoglobin (Hb) levels at baseline and weight, the patients received
1500, 2000, 2500 or 3000mg of iron isomaltoside infused in single doses up to 2000mg. The outcome
measurements included adverse drug reactions (ADRs) and changes in haematology and biochemistry
parameters.
Results: Twenty-one IBD patients with IDA were enrolled, receiving 1500 (seven patients), 2000 (eight
patients), 2500mg (four patients) or 3000 (two patients) mg of iron. No serious ADRs were observed.
Four patients experienced nine mild to moderate ADRs (hypersensitivity, pyrexia, vomiting, constipation,
abdominal pain, dyspepsia (two events) and eye allergy (two events)). In total, 15 (75%) patients had an
increase in Hb of 2.0 g/dL during the trial, with normalisation of ferritin. No changes in iFGF23 or clin-
ically significant hypophosphataemia were found.
Conclusion: Rapid infusions of high-dose iron isomaltoside, administered as single doses up to
2000mg and cumulative doses up to 3000mg, were without safety concerns and were efficacious in
increasing Hb levels in IBD patients. Iron isomaltoside did not induce profound phosphate wasting via
increased iFGF23 levels.
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Introduction
Iron deficiency anaemia (IDA) is a frequent complication of
inflammatory bowel disease (IBD), with a prevalence of
36–76% [1] and it is often not treated correctly despite it pos-
sibly impacting quality of life (QoL).[2–6]
According to several international guidelines, intravenous
(IV) iron reparation is preferred in the correction of moderate
to severe active IBD and IDA because it is more effective, it is
better tolerated and it improves QoL more rapidly than oral
iron supplements.[7,8]
Anaemic patients rarely have deficits less than 1000mg of
iron, and high doses of IV iron, up to 3600mg (administered
as multiple smaller doses), have been administered in IBD
patients.[8] However, if the full iron replacement dose could
be administered in fewer visits, then it would offer optimal
convenience to patients and would also improve the overall
pharmacoeconomics for both the patient and society.
Iron isomaltoside (MonoferVR , Pharmacosmos A/S, Holbaek,
Denmark) is high-dose IV iron for rapid infusion, and it can
be administered in doses exceeding 1000mg (maximum
20mg/kg body weight), providing the opportunity for iron
correction in one visit. Iron isomaltoside has previously been
shown to be safe and well tolerated in patients with
IBD,[9,10] chronic kidney disease,[11–13] and chronic heart
failure,[14] and in patients undergoing elective or subacute
coronary artery bypass graft procedures, valve replacement,
or a combination thereof.[15]
Whereas all parenteral irons can induce a small, transient
decrease in serum phosphate (s-phosphate), probably related
to increased erythropoiesis, some IV irons have been associ-
ated with phosphate wasting and potential clinically profound
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hypophosphataemia via intact fibroblast growth factor 23
(iFGF23)-induced urinary excretion of phosphate.[16]
The present trial was a prospective, non-comparative, open-
label, multi-centre, safety trial evaluating the safety of high sin-
gle doses and cumulative doses of iron isomaltoside in IBD
patients with IDA, including effect on iFGF23 and s-phosphate.
Methods
Trial design
A prospective, non-comparative, open-label, multi-centre, safety
trial was conducted from July 2012 to November 2014 at six sites:
three sites in Sweden, two sites in Denmark and one site in the
Netherlands. For the patients in group A, the trial duration was
approximately 10 weeks and they attended five visits (screening,
baseline, week 1, week 4 and week 8). For the patients in treat-
ment group B, the trial duration was approximately 18 weeks,
and each patient attended eight visits (screening, baseline, week
1, week 4, week 8, week 9, week 12 and week 16).
The primary objective of the trial was to assess the type
and incidence of adverse drug reactions (ADRs). The second-
ary objectives were changes in concentrations of haemoglo-
bin (Hb), s-iron, s-ferritin, TSAT, reticulocytes, s-phosphate,
iFGF23 and change in total QoL score (short-form health sur-
vey 12 Version 2 [SF-12 V2] and multidimensional fatigue
inventory 20 [MFI-20] questionnaires).
Participants
Patients who were 18 years of age, diagnosed with IBD in
remission or with disease activity and IDA (an Hb level of
<12 g/dL for women and Hb <13 g/dL for men) were eligible
to participate.
Patients were assessed as iron deficient if they had a
C-reactive protein (CRP) greater than the upper limit of nor-
mal (ULN) and a ferritin level <100 lg/L, whereas patients
with CRPULN had to have a ferritin level <30 lg/L.[7]
The full inclusion and exclusion criteria are shown in
Table S1.
Interventions
Based upon Hb level at baseline and weight, the patients
were divided into two treatment groups: A and B. The treat-
ment schedule is shown in Table 1.
The single dose of 1500mg was administered at baseline
in the 1500mg group, whereas the cumulative doses of
2000mg were administered in one or two doses (three
patients received 2000mg in one dose and five patients in
two doses), and the cumulative doses of 2500mg and
3000mg were administered in two doses.
All of the administrations of iron isomaltoside (MonoferVR ,
Pharmacosmos A/S, Holbaek, Denmark) were diluted in
100mL of normal saline (0.9% sodium chloride) and were
administered by infusion over approximately 15min.
During the trial, any concomitant medications or treat-
ments deemed necessary to provide adequate supportive
care were allowed. Blood transfusions, erythropoiesis-stimulat-
ing agent treatment and any iron supplementation other
than the investigational drug were prohibited.
Laboratory measurements of iFGF23 and phosphate
Intact FGF23 was measured using enzyme-linked immuno-
assay (Enzyme-linked Immunosorbent Assay Kit for FGF23,
Cloud Clone Corp, Houston, TX) with an intra-assay specificity
of <10% and inter-assay specificity of <12%. s-Phosphate
was evaluated as a part of the standard safety laboratory
assessment.
Sample size
There was no sample size calculation.
Table 1. Intravenous dosing regimen of iron isomaltoside in IBD patients with
iron deficiency anaemia.
Treatment
group Haemoglobin (Hb)
Iron isomaltoside
Body
weight <70 kg
Body
weight 70 kg
A Women: 10Hb <12 g/dL 1500mg 2000mga
Men: 11Hb <13 g/dL
B Women: Hb <10 g/dL 2500mgb 3000mgb
Men: Hb <11 g/dL
aDose administered over one or two visits.
bDose administered over two visits.
Table 2. Baseline demographics by infusion regime of intravenous iron isomaltoside.
Treatment Group A Treatment Group B
1500mg (N¼ 7) 2000mg (N¼ 8) 2500mg (N¼ 4) 3000mg (N¼ 2) Overall (N¼ 21)
Age (years)
N 7 8 4 2 21
Median (range) 30 (19–60) 52 (28–68) 44 (28–74) 34 (32–35) 41 (19–74)
Sex, N (%)
Men – 2 1 2 5 (24)
Women 7 6 3 – 16 (76)
Ethnicity, N (%)
Caucasian 5 8 4 2 19 (90)
Non-Caucasian 2 – – – 2 (10)
BMI (kg/m2)
N 7 8 4 2 21
Median (range) 24 (19–27) 28 (25–32) 22 (20–26) 23 (22–24) 25 (19–32)
Disease type, N (%)
Crohn’s disease 7 3 3 2 15 (71)
Ulcerative colitis – 5 1 – 6 (29)
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Statistical methods
In this safety trial, only one data set was constituted, i.e., the
safety analysis set (N¼ 21). The safety analysis set comprised
all patients who received at least one dose of the trial drug.
The primary safety data were tabulated. Descriptive statis-
tics for continuous variables were presented with numbers of
non-missing observations, means, standard deviations (SDs),
medians and ranges when appropriate. Categorical data were
presented by numbers of patients and percentages of obser-
vations in the various categories, where percentages were
based on the patients for whom relevant measurements were
obtained.
The changes in laboratory parameters over time were ana-
lysed and statistically evaluated with a repeated measures
mixed model, with treatment and day as factors and baseline
values as covariates. SASVR software, Version 9.1.3 (SAS
Institute Inc., Cary, NC), was used for the analyses.
Ethical considerations
The trial protocol was approved by local ethics committees
(Scientific Committees of Central Jutland no. 1-10-72-99-12)
and competent authorities (EudraCT no. 2011-003121-94), and
the trial was conducted in accordance with International
Conference on Harmonization guidelines for good clinical
practice and the Declaration of Helsinki of 1975, as revised in
1983.
The trial was registered on ClinicalTrials.gov (NCT01599702).
The patients were informed by the investigator of the risks
and benefits of the trial. Informed consent was obtained in
writing prior to any trial-related activities.
Figure 1. Changes from baseline in haemoglobin, s-ferritin, transferrin saturation and reticulocyte concentration over time in patients treated with 1500–2000mg iron
isomaltoside (group A) and 2500–3000mg iron isomaltoside (group B). Least square means (95% CIs) are derived from a repeated measures mixed model with treat-
ment and week as factors and baseline value as covariate. *p< 0.05, **p< 0.01, ***p< 0.001 (test for difference from baseline value).
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Results
Patients
A total of 39 patients were screened in the period from 24
July 2012 to 4 September 2014, during which 21 patients
were enrolled in group A (15 patients) and group B (six
patients). The last patient’s final visit was on 27 November
2014. Of the 21 patients enrolled, 20 (95%) patients com-
pleted the trial, and one (5%) patient discontinued due to
protocol non-compliance.
The patient demographics and baseline characteristics are
summarised in Table 2. The median age of the trial popula-
tion was 43 years old (range: 19–74 years). More women
(76%) than men (24%) participated and the majority of the
patients were Caucasian (91%).
Exposure to intravenous iron
All of the patients received the mean cumulative dose of iron
isomaltoside as planned.
Group A consisted of 15 patients (seven single dose
1500mg; three single dose 2000mg; five cumulative dose
2000mg [1500þ 500]).
Group B consisted of six patients (four cumulative doses of
2500mg [two patients: 2000þ 500; two patients: 1500þ 1000];
two patients with cumulative doses of 3000mg [one patient:
2000þ 1000; one patient: 1500þ 1500]).
Safety
All of the safety analyses were conducted on the safety ana-
lysis set (N¼ 21).
No patients experienced serious ADRs. A total of four
patients experienced nine mild to moderate ADRs (hypersen-
sitivity, pyrexia, vomiting, constipation, abdominal pain, dys-
pepsia (two events) and eye allergy (two events)).
The hypersensitivity event occurred in a 60-year-old woman
dosed with 1500mg of iron isomaltoside. Two days after dos-
ing, the patient developed an allergic reaction (hypersensitiv-
ity), from which she recovered fully two days later. The event
was mild and non-serious. No additional information was pro-
vided about the event. All cases were reported as recovered.
There were no fatal events during the trial.
Efficacy
Haemoglobin
Hb increased from a median (range) of 10.7 (9.3–12.9) g/dL at
baseline to 13.4 (11.3–14.5) g/dL at week 8 in Group A
(p< 0.0001, n¼ 14) and from 8.8 (6.8–10.5) g/dL to 12.4
(6.6–15.5) g/dL at week 16 in Group B (p< 0.0001, n¼ 6)
(Figure 1 and Table S2).
In total, 15 (75%) of 20 patients had an increase in Hb of
2.0 g/dL during the trial period.
s-Iron, s-ferritin, transferrin saturation and reticulocytes
There were increases in s-iron, s-ferritin and TSAT concentration
from baseline (Figure 1 and Table S2). There was a steady
increase in concentration of reticulocytes from baseline to
week 1, followed by a decrease throughout the trial.
Intact fibroblast growth factor 23 and phosphate levels
No overall changes in iFGF23 or clinically significant hypo-
phosphataemia were reported (Figure 2). The individual plots
of s-phosphate and iFGF23 are shown in Figure 3.
Two patients had transient events of moderate hypophos-
phataemia (s-phosphate level of 1-2mg/dL) (patients 11 and
18 in Figure 3). Both patients had s-phosphate levels greater
than 2mg/dL at all other visits. No patients experienced
severe hypophosphataemia (s-phosphate level <1mg/dL).
Quality of life score
There were no significant changes in average QoL score (SF-
12 version 2 and MFI-20) from baseline to week 8 in treat-
ment groups A and B and from baseline to week 16 in treat-
ment group B (Tables S3 and S4).
Discussion
In the present trial, we found no severe, serious or fatal ADRs.
All ADRs were non-serious, mild or moderate and IBD patients
with IDA received total cumulative doses of 1500–3000mg of
iron isomaltoside that were administered at 1–2 visits as sin-
gle doses of 500–2000mg; all recovered.
Anaemic IBD patients typically have been found to require
iron supplementation at a mean dose 1500mg of iron [17] or
even dose levels up to 3600mg has been reported.[18] Since
most parenteral iron preparations have dose limitations of
Figure 2. Change in iFGF23 and s-phosphate levels from baseline (blue line:
change from baseline to week 8 in all patients after first dosing) and week 8 (red
line: change from week 8 in patient dosed twice). Mean and 95% confidence
interval of mean.
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1000mg iron or less, the patients must undergo several
administrations/visits to reach the full iron requirement.
Iron isomaltoside can be administered in doses up to
20mg/kg body weight, enabling iron correction in one visit.
By reducing the frequency of administrations, compliance and
convenience for both patients and health care professionals
are improved. In general, there are a number of cost savings
associated with fewer IV iron infusions, including reduced
time off of work for the patient, travel and transportation
costs, equipment for administration, and time spent by the
hospital staff.[18,19]
The use of a larger dose for administration and thereby
fewer infusions might be an advantage because, according to
the European Medicines Agency, there is a risk of an allergic
reaction with every dose of IV iron that is administered,
although the reactions are rare.[20] By minimizing the num-
ber of administrations, the risk of a hypersensitivity reaction is
kept to a minimum.
The primary goal of iron supplementation therapy for IDA
is to increase Hb and s-ferritin to greater than the lower
threshold reference range to ensure replenished iron stores
and to increase QoL. The Hb improvement goal is to increase
Hb >2 g/dL or to restore Hb to normal levels (women: Hb
12 g/dL; men: Hb 13 g/dL) in four weeks.[8] In the present
trial, there were increases in Hb and s-ferritin. In total, 15
(75%) of 20 patients had an increase in Hb of 2.0 g/dL dur-
ing the trial period.
The reticulocyte count concentration increased from base-
line to week 1 in both treatment groups, followed by a
decrease. There was no change in average QoL scores, which
might have been due to the small number of patients and
the short duration of the trial.
Profound hypophosphataemia has previously been
reported with other IV iron preparations,[21] and clinical stud-
ies have suggested that prolonged and severely reduced s-
phosphate in response to IV iron could be caused by an
increase in iFGF23, leading to an increase in the excretion of
phosphate in the urine.[22,23]
FGF23 is a hormone produced by the osteocytes, and it
increases the rate of urinary excretion of phosphate and
inhibits renal production of 1,25-dihydroxyvitamin D
(1,25D).[24] A proportion of FGF23 is normally cleaved before
secretion, resulting in an intact, active hormone (iFGF23) and
biologically inactive C-terminal (cFGF23) fragments.[25] An
animal study showed that iron deficiency induced FGF23 tran-
scription in the osteocytes, but a counterbalancing increase in
FGF23 cleavage ensured that the level of iFGF23 was main-
tained. Thus, the level of iFGF23 was unchanged, whereas
cFGF23 was increased in iron-deficient animals.[26]
Wolf and colleagues evaluated the associations of IDA with
iFGF23 and cFGF23 levels in 55 women with heavy uterine
bleeding treated with equivalent doses of 1000mg of ferric
carboxymaltose or iron dextran.[16] Iron deficiency was asso-
ciated with markedly increased levels of cFGF23, but the
iFGF23 level was normal at baseline. After administration of
iron, cFGF23 decreased by approximately 80% in both treat-
ment groups, indicating that fgf transcription was normalised.
However, in women treated with ferric carboxymaltose,
iFGF23 increased with hypophosphataemia in 10 of 17
women, whereas women treated with iron dextran had nor-
mal levels of iFGF23 and no events of hypophosphataemia.
The authors suggested that the carbohydrate moieties in cer-
tain iron preparations, such as ferric carboxymaltose, might
temporarily increase iFGF23 levels by inhibiting the degrad-
ation of FGF23 in osteocytes, leading to hypophosphatae-
mia.[16] Similar findings were reported in a comparison of
iron sucrose and ferric carboxymaltose, in which ferric carbox-
ymaltose induced an increase in FGF23 and urinary phos-
phate wasting; this was not the case for iron sucrose.[27]
Hence, profound urinary phosphate wasting does not seem
to be a class effect of IV irons per se, but it might be a mech-
anism related to specific compounds that alter iFGF23 release,
which is not seen with iron sucrose [27] or iron dextran.[16]
In the present trial, two patients had transient events of
hypophosphataemia (s-phosphate level <2mg/dL) of 1.6 and
1.8mg/dL, and no significant changes in iFGF23 were
observed, even when iron isomaltoside was administered in
cumulative doses of up to 3000mg and single infusions of up
to 2000mg. Although this trial was based upon a small num-
ber of patients, it suggested that iron isomaltoside does not
induce hypophosphataemia through an FGF23-mediated
pathway despite the high iron doses administered that
exceeded the dosing applied in the trial by Wolf and
colleagues.
In conclusion, single high doses of iron isomaltoside, up to
2000mg within 15min, were well tolerated and considered
safe in patients with IDA secondary to IBD, and these doses
did not induce profound changes in phosphate or iFGF23 lev-
els after infusion. The safety profile of the high dosing regi-
men was in agreement with current knowledge about iron
isomaltoside safety in lower dosing regimens.
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